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ode rn me dic ine  has  e nable d a  
dras tic  incre as e  in the  ave rage  
life s pan of the  global popula tion. 
Re ce ntly, the  WHO re por te d tha t 
be twe e n 2000 and 2015 the  global ave rage  
life s pan incre as e d by 5  ye ars , the  la rge s t 
growth s ince  the  1960s  [ 1] . Sadly, it  is  with 
a  ce r ta in dark irony tha t this  miraculous  
improve me nt of he alth has  le d mankind into 
the  c lutche s  of ye t anothe r  malady: 
de me ntia . While  the  e xact e tiology of 
de me ntia  is  a  conte ntious  is s ue , a  unifying 
r is k fac tor  for  de me ntia  in a ll its  diffe re nt 
forms  is  age  [ 2] . T he  U.K. has  a lre ady 
ide ntifie d de me ntia , mos t promine ntly 
Alzhe ime r ’s  dis e as e , as  the  numbe r  one  
caus e  of de ath, ove r taking he ar t dis e as e  for  
the  fir s t  t ime  due  to an incre as ingly age d 
popula tion [ 3] . Fore cas ts  for  Alzhe ime r ’s  
pre vale nce  warn tha t this  dis e as e  will only 
be come  more  wide s pre ad, pote ntia lly 
quadrupling by 2050, with a  global cos t of 
care  burde n e xce e ding $2 tr illion USD [ 4] .  
 
While  de me ntia  has  only be gan captur ing 
me dia  he adline s  re la tive ly re ce ntly, the  
s c ie ntific  community has  be e n tackling the  
is s ue  for  quite  s ome  time  now, and a  
cons ide rable  amount of e ffor t  has  be e n 
inve s te d into bas ic  re s e arch and drug 
de ve lopme nt. Ye t, de s pite  this  e ffor t , to da te  
the re  are  only a  handful of s ymptomatic  
tre a tme nts  for  Alzhe ime r ’s  and not a  s ingle  
e ffe c tive  the rapy ame liora ting dis e as e  ons e t 
or  progre s s ion. T he  paucity of e ffe c tive  
the rapie s  combine d with the  incre as ing 
burde n of de me ntia  on s ocie ty has  prompte d  
 
global le ade rs  to cre a te  a  2025 de adline  for   
the  de ve lopme nt of a  s ingle  the rapy tha t can 
pre ve nt or  de lay Alzhe ime r ’s  [ 5] . While  this  
de adline  has  be e n adopte d by the  fie ld, the  
na ture  of drug de ve lopme nt is  full of pitfa lls  
and once  promis ing candidate s  have  
re ce ntly fa lle n by the  ways ide . Is  2025 s till 
an achie vable  goal? And if s o, how can 
gove rnme nt polic ie s  he lp achie ve  it?  
 
T his  pas t autumn, the  pharmace utica l giant 
Eli Lilly  announce d tha t the ir  once  toute d 
Alzhe ime r ’s  drug s olane zumab has , a las , 
fa ile d its  third and fina l a tte mpt to pas s  
c linica l tr ia ls  [ 6] . T his  s hould be  no s urpr is e  
to a  fie ld tha t has  witne s s e d ove r  400 fa ile d 
the rapie s  s ince  2003 [ 7] , and, to mos t 
e xpe r ts , it  was  not. Howe ve r , gros s  ove r -
s ta te me nts  of s olane zumab’s  pre liminary 
re s ults  by the  me dia , with c la ims  about 
re ne we d hope  for  Alzhe ime r ’s  s uffe re rs  tha t 
a  promis ing the rapy was  immine nt, has  no 
doubt le ft  s ome  pe ople  de s ponde nt about the  
pos s ibility  for  a  viable  the rapy to be  
de ve lope d on a  re le vant t ime s cale  [ 8] . Why 
did Eli Lilly’s  tr ia l fa il? Why has  this  road, in 
ge ne ra l, be e n s o pe r ilous ? T o try to ans we r  
the s e  que s tions  one  has  to look de e p into 
the  na ture  of the  dis e as e . As  me ntione d 
br ie fly above , the  mole cular  or igin of 
Alzhe ime r ’s  and othe r  de me ntias  is  s till a  
de bate d is s ue . One  of the  mos t we ll-
s uppor te d hypothe s e s , te rme d the  amyloid 
hypothe s is , pos its  tha t aggre gation of 
ce r ta in mis folde d prote ins  in par ts  of the  
bra in is  the  caus ative  age nt of Alzhe ime r ’s  
and many othe r  de me ntias . A ple thora  of 
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tr e a tme nts  bas e d on this  hypothe s is  have  
gone  into tr ia ls  a tte mpting to ta rge t this  
pa thoge nic  aggre gation, inc luding 
s olane zumab, ye t none  have  produce d a  
s ignificant c linica l outcome . T he  lack of 
s ucce s s  of the s e  candidate  the rapie s  has  
s e r ious ly ca lle d into que s tion the  va lidity of 
the  amyloid hypothe s is . Howe ve r , the  na ture  
of this  aggre gation proce s s  is  incre dibly 
comple x , with many s tage s  of de ve lopme nt, 
and the  pa thoge nic  phas e s  of aggre gation 
are  only re ce ntly be coming we ll 
charac te r ize d [ 9] . T his  gap in the  
fundame nta l unde rs tanding of dis e as e  
or igins  has  cre a te d a  poor ly informe d drug 
de s ign proce s s  tha t has  ultimate ly doome d 
s ome  candidate s  from the  outs e t.  
Mos t dis e as e s  hav e  s udde n w e ll-
de fine d s y m ptom s , but is n’t  
forge tfulne s s  jus t a part of  age ing? 
Anothe r  obs tac le  unique  to de me ntia  
tre a tme nt tha t could have  playe d a  role  in 
s olane zumab’s  fa ilure  is  the  difficult  
diagnos is  of the s e  dis e as e s . Mos t dis e as e s  
have  s udde n we ll- de fine d s ymptoms , but 
is n’t  forge tfulne s s  jus t a  par t  of age ing? 
How do you know whe n you s hould be  
conce rne d? De te rmining if a  family me mbe r  
is  s uccumbing to Alzhe ime r ’s  is  pe rhaps  the  
mos t difficult  s te p in de aling with this  
dis e as e . In fac t, be caus e  aging is  as s ocia te d 
with the  s te re otype  of be coming forge tful or  
lackadais ica l, Alzhe ime r ’s  was  only 
re cognize d as  a  dis e as e  jus t ove r  a  ce ntury 
ago, due  to the  obs e rvation of an e x tre me ly 
e ar ly ons e t, he r itable  form of the  dis e as e . 
T o be  c le ar , de me ntia  is  abs olute ly not 
normal aging. But the  ge ne ra lly s low 
progre s s ion of the s e  dis e as e s  and the  
re liance  on re la tive ly ins e ns itive  cognitive  
te s ts  a t  e ar ly s tage s  make s  the ir  t ime ly 
diagnos is  incre dibly difficult  [ 4] . T his  
challe nge  could have  affe c te d s olane zumab’s  
tr ia l be caus e  the  s tage  of the  aggre gation 
proce s s  tha t it  is  mos t like ly to impact 
s ignificantly, bas e d on its  r e por te d ta rge t, 
occurs  ve ry e ar ly in dis e as e  progre s s ion, 
and s ome  me dica l profe s s ionals  be lie ve  it  
might have  s ucce e de d if Eli Lilly  had 
a tte mpte d an e ar lie r  tr e a tme nt [ 6] . 
Howe ve r , this  would ne ce s s ita te  a  la rge  
pool of s ubje c ts  who have  be e n ide ntifie d as  
high r is k for  the  dis e as e  and ye t be  la rge ly 
as ymptomatic , which is  ve ry difficult  for  a  
dis e as e  tha t lacks  e ar ly de te c tion bio-
marke rs .  
 
T he s e  fe w re as ons , a long with many othe rs , 
have  contr ibute d to the  pe r ilous  na ture  of 
Alzhe ime r ’s  drug de ve lopme nt. So, what is  
the  pos s ibility  tha t the  fie ld ove rcome s  
the s e  hurdle s  and de live rs  on the  2025 
de adline ? For  an accura te  as s e s s me nt, 
Cummings  e t a l. [ 4]  re ce ntly approache d 
this  que s tion by working backwards  from 
2025. From de ve lopme nt on through 
re gula tory re vie w, the y c la im an Alzhe ime r ’s  
drug would take  ove r  9  ye ars  to ga in Food 
and Drug Adminis tra tion (FDA) approval, 
with mos t of tha t t ime  s pe nt in Phas e  2  and 
3  of c linica l tr ia ls . T hat me ans  tha t a t  the  
la te s t , a  candidate  mus t s tar t  Phas e  3  tr ia ls  
by 2019. T he re  is  a  pre ce de nt, howe ve r , for  
ce r ta in tr ia ls  to ge t a  “Bre akthrough 
T he rapy De s ignation” and re ce ive  an 
e xpe dite d track through tr ia ls , which could 
be  appropr ia te  if a  promis ing AD the rapy 
come s  a long la te r  in the  time line . According 
to public  re cords , the re  are  only 38 
amyloid- re la te d the rapie s  cur re ntly 
unde rgoing c linica l tr ia ls  and a  s imilar  
numbe r  of tr ia ls  ta rge ting othe r  e ntit ie s  
within Alzhe ime r ’s  s uch as  inflammation 
[ 10] ; if the  notor ious ly high a ttr it ion ra te  of 
the  pas t continue s  this  may not be  e nough to 
e ns ure  the  de adline  is  me t. T hat’s  not to s ay 
tha t s ome  the rapie s  cur re ntly in tr ia ls  a re  
not promis ing -  Bioge n has  re ce ntly 
publis he d a  thorough s c ie ntific  s tudy 
s howing the ir  drug aducanumab s ignificantly 
re duce s  aggre gation in e ar ly c linica l s tudie s  
[ 11] . But if anything has  be e n le arne d from 
Eli Lilly’s  fa ilure , it’s  not to blow pre liminary 
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re s ults  out of propor tion; aducanumab is  
continuing on in phas e  3  tr ia ls  and it  will be  
ve ry inte re s ting to s e e  the  outcome .  
 
If the  cur re nt cohor t of tr ia ls  prove s  
fruitle s s , can re s e arche rs  a tte mpt to provide  
a  tre a tme nt s oon afte r  2025? Afte r  a ll, the  
de adline  was  not s e t s tr ic tly with the  
re a lit ie s  of drug de ve lopme nt in mind, but 
ra the r  as  a  hope ful goal de cide d by 
gove rnme nt offic ia ls  bas e d on pre vale nce  
fore cas ts . One  a ttrac tive  route  is  drug 
re purpos ing. T his  involve s  s cre e ning 
a lre ady FDA approve d drugs  for  var ious  
dis e as e s  to s e e  if the y s e re ndipitous ly a ls o 
have  an e ffe c t on Alzhe ime r ’s  pa thoge ne s is . 
Inde e d, this  approach has  re ce ntly ide ntifie d 
a  s mall mole cule  tha t has  s ignificant e ffe c ts  
on aggre gation and is  cur re ntly us e d as  an 
anti- cance r  tre a tme nt [ 12] . Since  the s e  
drugs  have  a lre ady had the ir  tox ic ity and 
long- te rm s ide  e ffe c ts  e valuate d in pre vious  
s tudie s , the y could pote ntia lly be gin a t 
phas e  2  of c linica l tr ia ls  as s e s s ing e fficacy 
for  tre a ting Alzhe ime r ’s , s hor te ning the ir  
t ime  to approval by ye ars  pote ntia lly [ 4] . 
Howe ve r , a  major  is s ue  with this  approach, 
from the  pe rs pe ctive  of indus try, is  tha t 
the s e  re purpos e d drugs  may not be  
pa te ntable , gre a tly lowe r ing the  ince ntive  
for  the ir  imple me nta tion from a  fis ca l 
s tandpoint.  
 
T he  2025 de adline  is  an ambitious  goal, but 
the  dr ive  tha t come s  from s tr iving towards  
this  da te  is  e xactly what is  ne e de d to ke e p 
the  s courge  of de me ntia  a t  bay. Re s e arche rs  
are  working ve ry hard to unrave l the s e  
comple x  dis e as e s , but to me e t this  goal the y 
ne e d a ll the  he lp and re s ource s  tha t can be  
mus te re d. One  thing for  ce r ta in is  tha t the  
funding for  de me ntia  re s e arch is  gros s ly out 
of propor tion with its  growing impor tance . 
T o put this  in pe rs pe ctive , in the  U.K. 
cance r  re s e arch re ce ive s  approx imate ly 5  
time s  the  amount of funding compare d to 
de me ntia , e ve n though de me ntia’s  cos t of 
care  burde n on the  country is  a lre ady ove r  
double  tha t of cance r  [ 13] . If gove rnme nt 
offic ia ls  a re  s e r ious  about the  2025 
de adline , and want to a id in any way 
pos s ible , this  dis cre pancy in funding mus t be  
br idge d if we  are  to truly r id the  wor ld of 
the s e  dis e as e s  in an e ffic ie nt manne r .  
 
At this  point in t ime , 2025 is  s till an 
achie vable  goal for  the  de ve lopme nt of a  
s ingle  e ffe c tive  Alzhe ime r ’s  tr e a tme nt; with 
promis ing drugs  like  aducanumab s till in 
tr ia ls  no one  s hould give  into de s pair . But, 
the  me mory of Eli Lilly’s  e xpe r ie nce  s hould 
be  ke pt in mind. We  a ls o s till mus t cons ide r  
pos t- 2025, e ve n if this  goal is  me t and a  
the rapy ar r ive s  by the n, tha t is  by no me ans  
the  e nd of the  de me ntia  s tory. Much work 
will s till ne e d to be  inve s te d in the  tre a tme nt 
of othe r  de me ntias  be s ide s  Alzhe ime r ’s , and 
in othe r  as pe cts  s uch as  de ve loping bio-
marke rs  for  e ar ly de te c tion and advance d 
me dica l imaging te chnique s  to as s is t  with 
tre a tme nt de c is ions . All this  and more  can 
be  as s is te d on the  policy s ide  if the  
re s ource s  available  to de me ntia  re s e arche rs  
match its  indis putable  impor tance  to the  
future  of global he a lth. Age  is  jus t a  numbe r , 
and e ve n though mode rn me dic ine  has  
ra is e d tha t numbe r  highe r  than e ve r  be fore , 
it  is  me aningle s s  if the  incre as e  is  
concomitant with a  s tark de cre as e  in the  
quality  of life . It  is  t ime  for  this  dis cre pancy 
to be  s e r ious ly de alt  with and place  
de me ntia  a t  the  fore front of me dica l 
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